Regulation of Collagen-Rich Matrix Remodeling in Wound Healing, Inflammation and Cancer

E. Puré^{*} and Priya Govindaraju

Department of Biomedical Sciences, University of Pennsylvania, Philadelphia, PA 19104, USA

Abstract: CD44 plays multiple roles in the context of inflammation and cancer including leukocyte recruitment, activation, and intratumoral migration [1,2]. CD44 also plays a role in the uptake of its principal ligand, hyaluronic acid (HA), and accumulation of soluble factors involved in stromal cell activation [1,2]. The role of CD44 in matrix remodeling is less well understood. Wound healing, inflammation and the microenvironment of solid tumors are all characterized by the accumulation and remodeling of HA and collagen-rich extracellular matrices. We have found that genetic deletion of CD44 results in increased fibrillar collagen accumulation in each of these conditions and that this phenotype is recapitulated in isolated fibroblast-derived matrices generated by CD44-deficient fibroblasts compared to wild-type fibroblasts *in vitro*. The mechanisms underlying CD44-mediated matrix remodeling and the consequences of altered matrix remodeling in each of these conditions in CD44-deficient mice compared to wild-type mice were discussed.

OVERVIEW

The overlap between many of the pathophysiologic processes involved in wound healing, chronic inflammatory and fibrotic diseases as well as cancer has been well characterized [3]. Similar analogies arguably apply in the context of autoimmunity. The shared hallmarks of all these pathologic conditions include a dysfunctional vasculature, angiogenesis, stromal cell activation and matrix remodeling. These processes are all highly regulated by cell-cell interactions involving epithelial cells, inflammatory and immune cells, endothelial cells, mesenchymal stromal cells such as fibroblasts and the hematogenous and lymphatic vasculatures [3]. These processes are also cell-matrix dependent on interactions. Matrix remodeling is a quintessential feature of all these processes that modulates biomechanical, biophysical and biochemical signaling that governs cell behavior to orchestrate the integrated response. The transmembrane adhesion receptor CD44 can mediate both cell-cell and cell-matrix interactions through its regulated affinity for HA and/or as a docking platform for matrix proteins, matrix modifying enzymes and growth factors [1,2] (Figure 1). Myriad studies have implicated CD44 in linking extracellular cues to intracellular signals that impact cytoskeletal organization, proliferation, angiogenesis and cell polarity. Furthermore, post-translational modification, splicing, and proteolysis of membrane bound CD44 can alter CD44-HA signaling and CD44 activity. To define the impact of the many functions of CD44 on wound healing, inflammation/fibrosis and cancer, we compared responses and outcome in each of these contexts between wild-type and CD44-null mice. Results of these studies were presented.

IMPACT OF CD44 ON CUTANEOUS WOUND HEALING

Cutaneous wound healing occurs through blood clotting, inflammation, re-epithelialization and tissue remodeling [4,5]. Stromal cell-dependent tissue remodeling involves dynamic restructuring of the fibrillar collagen rich ECM. Typically, the response to injury is self-limiting and leads to restoration of normal skin function and biomechanics. However, persistent accumulation of fibrillar collagen, the principal ECM protein found in the skin, can result in hypertrophic scar formation and highly compromised skin function and aberrant biomechanical properties compared to normal skin [6]. HA, the predominant glycosaminoglycan associated with the injury response, is upregulated early following injury and persists during wound healing [7,8]. Furthermore, evidence suggests that HA regulates collagen accumulation and impacts collagen architecture and thereby influences the outcome of wound healing. Thus, defining mechanisms that govern ECM dynamics is vital to understanding normal versus pathological hypertrophic scarring and developing approaches to prevent scarring.

Although CD44, the principal receptor for HA has been implicated in an array of inflammatory and fibrotic processes such as leukocyte recruitment, T-cell extravasation, and HA metabolism, the role of CD44 in cutaneous wound healing and fibrillar collagen accumulation remains unknown. To define the role of CD44 we compared wound healing in wild-type (WT)

^{*}Address correspondence to this author at the Department of Biomedical Sciences, University of Pennsylvania, Philadelphia, PA 19104, USA; Tel: 215.573.9406; Fax: 215.573.6810; E-mail: epure@vet.upenn.edu



Figure 1: Mechanisms of CD44-dependent cell-cell and cell matrix interactions. CD44 is a cell surface adhesion receptor that plays a vital role in cell-ECM and cell-cell interactions through association with its primary ligand hyaluronic acid (HA), by functioning as a docking platform for matrix metalloproteinases (MMPs) and growth factors, by integration of a soluble form of its extracellular domain (sCD44) into the matrix, by signal transduction and/or by proteolytic release of its intracellular domain (CD44-ICD) that can regulate gene transcription. The extracellular domain of CD44 contains a Bx7B HA binding motif. CD44-HA binding of the transmembrane form of the receptor allows for the retention of HA on cell surface as major component of the glycocalyx and HA synthesis and turnover. The extracellular domain of CD44 is subject to extensive alternative splicing as well as multiple post-translation modifications including glycosylation and sulfation that can modulate its ligand affinity and activity. The intracellular domain of CD44 is itself subject to phosphorylation [11,12] and regulates phosphorylation of CD44 intracellular binding partners. The intracellular domain of CD44 can form complexes with merlin and ezrin/radixin/moeisin (ERM) [11,12]. Phosphorylation of ERM induces actin cytoskeleton remodeling and cell proliferation. Dephosphorylated merlin binds to CD44-ICD [13,14] and initiates cell cycle arrest by inhibiting Rac GTP, which is required for cyclin D1 induction. CD44 can also act as a docking platform for various proteins, enzymes, and growth factors that play a crucial role in ECM deposition and assembly such as fibroblast growth factor (FGF), collagen, osteopontin, and matrix metalloproteinases (MMPs) [2,15]. Collagenases, MMP9 and MMP7, have been shown to co-precipitate with CD44, even in the presence of CD44-HA blocking antibodies [16,17]. Additionally, optimal activation of TGF-B, a vital growth factor implicated in stromal cell activation and collagen deposition, is CD44-dependent [18]. In the context of a tumor microenvironment, hepatocyte growth factor (HGF)-induced cMet activation depends on CD44 [19]. The extracellular domain of CD44 (sCD44) released upon MT1-MMP-dependent cleavage can retain ligand affinity and can compete with membrane bound CD44 for HA binding, therefore altering CD44-HA dependent signaling and the extracellular milieu [20]. Under elevated conditions of dynamic matrix remodeling or high proteolytic activity, the release of sCD44 is followed by presenilin 1-dependent gamma secretase mediated proteolysis of the intracellular domain of CD44 thus liberating CD44-ICD [13]. CD44-ICD translocates to the nucleus and can induce transcription of various ECM related genes including CD44 itself, MMP9, MMP2, and Hif1a.

and CD44 global knockout mice using a punch-biopsy injury model. We found that CD44-deficient mice exhibit increased collagen synthesis leading to increased accumulation of fibrillar collagen at wound closure compared to WT mice. This increase in fibrillar collagen accumulation persisted after wound closure thus, recapitulating a more severe scarring phenotype. These data indicate that CD44 plays a previously unknown role in fibrillar collagen accumulation during the response to cutaneous injury. We are currently investigating the mechanisms by which CD44-mediated signaling and/or CD44-ECM interactions regulates the dynamics of fibrillar collagen and thereby contributes to normal wound repair and the impact of CD44 deletion on the functionality of scar tissue.

ROLE OF CD44 IN PANCREATITIS AND PANCREATIC CARCINOGENESIS

Pancreatitis is a well-known risk factor for the development of pancreatic cancer [9]. We used an experimental model of caerulein-induced acute pancreatitis to investigate the role of CD44 in the context of pancreatitis. We found that early pancreatitis was attenuated, and that resolution of pancreatitis was accelerated, in CD44-null compared to wild-type mice.

Excess accumulation of HA is a hallmark of pancreatic ductal adenocarcinoma (PDA) and recent evidence indicates that HA in this context confers resistance to therapy [10]. There are multiple potential approaches to target this increased HA accumulation including inhibition of HA synthesis, depletion of HA by treatment with hyaluronidases and blocking receptormediated HA signaling. To determine if targeting CD44 may provide a novel therapeutic approach to the treatment of PDA and to overcoming resistance of this disease to conventional therapies, we investigated the impact of genetic deletion of CD44 on tumor growth in an orthotopic transplant model of PDA. We found that CD44-null mice exhibited reduced tumor burden that was associated with an increase in collagen accumulation. Current studies are focused on the mechanisms by which CD44 exacerbates injuryinduced pancreatitis and supports the growth of pancreatic cancer.

REFERENCES

- [1] Naor D, Sionov RV, Ish-Shalom D. CD44: Structure, function, and association with the malignant process. Advances in Cancer Research 1997; 71: 241-319. <u>https://doi.org/10.1016/S0065-230X(08)60101-3</u>
- [2] Puré E, Assoian RK. Rheostatic signaling by CD44 and hyaluronan. Cell Signal 2009; 21: 651-655. <u>https://doi.org/10.1016/j.cellsig.2009.01.024</u>
- [3] Rybinski B, Franco-Barraza J, Cukierman E. The wound healing, chronic fibrosis, and cancer progression triad. Physiological Genomics 2014; 46: 223-244. <u>https://doi.org/10.1152/physiolgenomics.00158.2013</u>
- [4] Singer AJ, Clark RA. Cutaneous Wound Healing. New England Journal of Medicine 1999; 341: 748-746. <u>https://doi.org/10.1056/NEJM199909023411006</u>

- [5] Flanagan F. The Physiology of Wound Healing. Journal of Wound Care 2000; 9: 299-300. <u>https://doi.org/10.12968/jowc.2000.9.6.25994</u>
- [6] Gurter CG, Werner S, Barrandon Y, Longaker TM. Wound Repair and Regeneration. Nature Insight Review 2008; 435: 314-321.
- [7] Dillon PW, Keefer K, Blackburn JH, Houghton PE, Krummel TM. The extracellular matrix of the fetal wound: Hyaluronic Acid Controls Lymphocyte Adhesion. Journal of Surgical Research 1994; 57: 170-173. https://doi.org/10.1006/isre.1994.1126
- [8] Mast BA, Haynes FH, Krummel TM, Cohen IK. In Vivo Degradation of Fetal Wound Hyaluronic Acid Results in Increased Fibroplasia, Collagen Deposition, and Neovascularization. Plastic and Reconstructive Surgery 1992; 83: 503-509. https://doi.org/10.1097/00006534-199203000-00019
- [9] DiMagno MJ, DiMagno EP. Chronic Pancreatitis. Curr Opin Gastroenterology 2009; 25: 454-459. https://doi.org/10.1097/MOG.0b013e32832e1600
- [10] Provenzano PP, Cuevas C, Chang AE, Goel VK, Von Hoff DD, Hingorani SR. Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell 2012; 21: 418-429. <u>https://doi.org/10.1016/j.ccr.2012.01.007</u>
- [11] Tsukita S, Oishi K, Sato N, Sagara J, Kawai A, Tsukita S. ERM family members as molecular linkers between the cell surface glycoprotein CD44 and actin based cytoskeletons. Journal of Cell Biology 1994; 126: 391-401. https://doi.org/10.1083/jcb.126.2.391
- [12] Bretscher A, Edwards K, Fehon RG. ERM proteins and merlin: integrators at the cell cortex. Nature Reviews Molecular Cell Biology 2002; 3: 586-599. https://doi.org/10.1038/nrm882
- [13] Okamoto I, Kawano Y, Murakami D, Sasayama T, Araki N, Miki T, Wong AJ, Saya H. Proteolytic release of CD44 intracellular domain and its role in the CD44 signaling pathway. Journal of Cell Biology 2001; 155: 755-762. <u>https://doi.org/10.1083/jcb.200108159</u>
- [14] Miletti-González KE, Murphy K, Kumaran MN, Ravindranath AK, Wernyj RP, Kaur S, *et al.* Identification of function for CD44 intracytoplasmic domain (CD44-ICD): modulation of matrix metalloproteinase 9 (MMP-9) transcription via novel promoter response element. Journal of Biological Chemistry 2012; 287: 18995-19007. https://doi.org/10.1074/jbc.M111.318774
- [15] Louderbough JMV, Schroeder JA. Understanding the dual nature of CD44 in breast cancer progression. Molecular Cancer Research 2011; 9: 1573-1586. https://doi.org/10.1158/1541-7786.MCR-11-0156
- [16] Yu Q, Stamenkovic I. Localization of matrix metalloproteinase 9 to the cell surface provides a mechanism for CD44-mediated tumor invasion. Genes and Development 1999; 13: 35-48. <u>https://doi.org/10.1101/gad.13.1.35</u>
- [17] Yu Q, Stamenkovic I. Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Genes and Development 2000; 14: 163-76.
- [18] Acharya PS, Majumdar S, Jacob M, Hayden J, Mrass P, Weninger W, Assoian RK, Pure E. Fibroblast migration is mediated by CD44-dependent TGF-beta activation. Journal of Cell Science 2008; 121: 1393-1402. <u>https://doi.org/10.1242/jcs.021683</u>
- [19] Orian-Rousseau V, Chen L, Sleeman JP, Herrlich P, Ponta H. CD44 is required for two consecutive steps in HGF/c-Met signaling. Genes and Development 16: 3074-3086. <u>https://doi.org/10.1101/gad.242602</u>

[20] Cichy J, Bals R, Potempa J, Mani A, Puré E. Proteinasemediated release of epithelial cell-associated CD44. Extracellular CD44 complexes with components of cellular matrices. Journal of Biological Chemistry 2002; 277: 44440-44447. https://doi.org/10.1074/ibc.M207437200

Received on 01-11-2017

Accepted on 30-11-2017

Published on 31-12-2017

DOI: https://doi.org/10.12970/2310-9874.2017.05.07

© 2017 Puré and Govindaraju; Licensee Synergy Publishers.

This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (<u>http://creativecommons.org/licenses/by-nc/3.0/</u>) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.